| Name | Title | Contact Details |
|---|
Introba is one of the worlds largest building engineering and consulting firms with more than 1,000 employees in offices across the United States, Canada, the United Kingdom, Serbia, and Australia. Committed to reshaping the world, our problem solvers combine cutting-edge digital solutions with emerging innovations and industry-leading sustainability strategies to transform the built environment. We collaborate with our clients to create living systems that are smart, secure, resilient, and connected – spaces that uplift communities, protect the health of the planet, and adapt to meet the demands of the future.
When it comes to the world of automotive components, JVIS has continued to be the supplier of choice for leading global brands. Why? Were fast. Were flexible. Were everywhere. With our extensive art-to-part capabilities, we can do whatever it takes to help our customers get the solution they need. And facilities around the world and an international network of dedicated partners — we can provide global services with localized support you cant get from other suppliers. Thats great news for both your production line and bottom line. Whether you need a sleek new exterior part or a complete interior solution that creates a more comfortable ride, our team of experts can quickly design, produce and deliver exactly what you need.
The Louis D. Brandeis Center, Inc. (LDB) is an independent, non-partisan institution for public interest advocacy, research and education. The Centers mission is to advance the civil and human rights of the Jewish people and to promote justice for all.
Robert Reynolds, a high-stakes corporate lawyer with law firms such as Alston & Bird and Seyfarth Shaw, and award-winning innovator in the legal space, founded Tangible Global in 2014 with the mission to bring the practice of law into modern times delivering "Law at the speed of business." Joining Robert as Partner, Denise Barnes brings over 20 years of experience as a seasoned entrepreneur in B2B service delivery. Her marketing firm was the first to offer marketing automation, managed services, and digital applications to clients such as Microsoft, Oracle, and Google. With its recent acquisition of AUTTO, a leading no-code technology and applications provider, Tangible further strengthened its technology and software development leadership by adding Ian Gosling as CPO and Krisztian Kerek as CTO. Nike, one of Tangibles early adopters, embraced and understood that Tangible represented a better alternative to the traditional law firm providing great value especially for portfolios of recurring transactions. Nike has continued to partner with Tangible over the last 10 years. AUTTO has been embraced by the global law firms of Eversheds Sutherland and Dentons as well as Petronas. By combining no-code workflow automation capabilities with extensive legal expertise across many industries, Tangible continues to evolve its broad portfolio of digital applications that support various aspects of commercial transactions and legal operations. AUTTOs technology has enabled Tangible to develop digital services to replace "time with tech." By combining AUTTOs workflow automation capabilities with extensive legal expertise across many industries, the firm has developed a broad portfolio of digital services to support various aspects of commercial transactions and legal operations, including an AI risk management service. Headquartered in Portland, OR, Tangibles team members are distributed across the US, with a notable presence in New York, London, Boston, and Chicago.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.